文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate.

作者信息

Mirmoezzi Hamed, Koochak Hamid Emadi, Dehghan Manshadi Seyed Ali, Hasannezhad Malihe, SeyedAlinaghi SeyedAhmad, Semnani Kiavash, Abbasian Ladan, Ghaderkhani Sara

机构信息

School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Department of Infectious Diseases, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tehran, Iran.

出版信息

AIDS Res Ther. 2025 Mar 15;22(1):35. doi: 10.1186/s12981-025-00728-6.

DOI:10.1186/s12981-025-00728-6
PMID:40089788
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11909937/
Abstract

Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil fumarate (TDF). We retrospectively evaluated changes in weight and glucose regulation among 153 treament-naïve patients. Weight-gain was more pronounced after one year of treatment with TAF versus TDF (3.5 kg versus - 1 kg, P-value < 0.001). However, weight-gain was attenuated with longer follow-up, and no increase in glucose dysregulation was noted for TAF treatment. Attribution of increased metabolic risk to treatment with TAF remains questionable.

摘要

相似文献

[1]
Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate.

AIDS Res Ther. 2025-3-15

[2]
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.

Ann Intern Med. 2021-6

[3]
Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV.

Clin Infect Dis. 2024-10-15

[4]
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.

Int J Infect Dis. 2020-1-25

[5]
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.

Infection. 2018-9-29

[6]
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.

Clin Infect Dis. 2024-6-14

[7]
Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.

Int J STD AIDS. 2021-5

[8]
Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.

HIV Med. 2024-9

[9]
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.

AIDS Res Ther. 2025-4-7

[10]
Tenofovir alafenamide promotes weight gain and impairs fatty acid metabolism-related signaling pathways in visceral fat tissue compared to tenofovir disoproxil fumarate.

Antiviral Res. 2025-5

本文引用的文献

[1]
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.

JAMA. 2025-2-18

[2]
Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives.

Life (Basel). 2024-10-24

[3]
Effect of 2 Forms of Tenofovir on Duodenal Enterocytes-A Hypothesis for Different Effect of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide on Body Weight and Plasma Lipids.

Clin Infect Dis. 2025-2-24

[4]
Which Form of Tenofovir Should Be Used Worldwide: Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide?

Clin Infect Dis. 2024-10-15

[5]
Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV.

Clin Infect Dis. 2024-10-15

[6]
Antiretroviral therapy and weight gain in antiretroviral treatment-experienced HIV patients: A review.

AIDS Rev. 2023

[7]
Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study.

AIDS Res Hum Retroviruses. 2023-2

[8]
Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States.

J Health Econ Outcomes Res. 2022-2-14

[9]
Tenofovir alafenamide (TAF) clinical pharmacology.

Infez Med. 2021-12-10

[10]
Impact of Combined Antiretroviral Therapy on Metabolic Syndrome Components in Adult People Living with HIV: A Literature Review.

Viruses. 2022-1-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索